Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26618847 | 0.76 | MEN1 (0.38) | MEN1KMT2AALDH1A1TDP1CASP1 | |
| SCHEMBL13617559 | 0.76 | — | — | |
| SCHEMBL9253799 | 0.74 | CASP1 (0.37) | MEN1KMT2AALDH1A1TDP1CASP1 | |
| SCHEMBL15134523 | 0.74 | MEN1 (0.36) | MEN1KMT2AALDH1A1TDP1CASP1 | |
| SCHEMBL4756149 | 0.74 | MEN1 (0.45) | MEN1KMT2AALDH1A1TDP1CASP1 | |
| SCHEMBL2498368 | 0.74 | MEN1 (0.36) | MEN1KMT2AALDH1A1TDP1CASP1 | |
| SCHEMBL30140506 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHR | |
| SCHEMBL2223922 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL24720928 | 0.70 | ALDH1A1 (0.35) | MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL26622353 | 0.69 | CYP3A4 (0.35) | MEN1KMT2ACASP1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | PFIZER INC. | 2009-12-03 | — | — | US | disclosed |
| EP-2017259-A2 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | Pfizer Products Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| CN-101341117-A | Preparation of Y-amino acids having affinity for the alpha-2-delta protein | PFIZER (US) | 2009-01-07 | — | — | CN | disclosed |
| WO-2008155619-A2 | PREPARATION OF OPTICALLY-ACTIVE CYCLIC AMINO ACIDS | PFIZER INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | SCN2A, CACNG2, SCN1A | MEN1 2756/4885KMT2A 3394/4885ALDH1A1 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.